JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 11, 2003; DOI: 10.1124/jpet.102.048454

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.102.048454v1
305/2/608    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janovick, J. A.
Right arrow Articles by Conn, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janovick, J. A.
Right arrow Articles by Conn, P. M.

Vol. 305, Issue 2, 608-614, May 2003

Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor

Jo Ann Janovick, Mark Goulet, Eugene Bush, Jonathan Greer, David G. Wettlaufer and P. Michael Conn

Oregon Health and Science University/Oregon National Primate Research Center, Beaverton, Oregon (J.J., P.M.C.); Merck Research Laboratories, Rahway, New Jersey (M.G.); Abbott Laboratories, Abbott Park, Illinois (E.B., J.G.); TAP Pharmaceutical Products, Inc., Lake Forest, Illinois (D.G.W.)

We expressed a test system of wild-type (WT) rat (r) and human (h) gonadotropin-releasing hormone (GnRH) receptors (GnRHRs), including naturally occurring (13) and manufactured (five) "loss-of-function" mutants of the GnRHR. These were used to assess the ability of different GnRH peptidomimetics to rescue defective GnRHR mutants and determine their effect on the level of membrane expression of the WT receptors. Among the manufactured mutants were the shortest rGnRHR C-terminal truncation mutant that resulted in receptor loss-of-function (des325-327-rGnRHR), two nonfunctional deletion mutants (des237-241-rGnRHR and des260-265-rGnRHR), two nonfunctional Cys mutants (C229A-rGnRHR and C278A-rGnRHR); the naturally occurring mutants included all 13 full-length GnRHR point mutations reported to date that result in full or partial human hypogonadotropic hypogonadism. The 10 peptidomimetics assessed as potential rescue molecules ("pharmacoperones") are from three differing chemical pedigrees (indoles, quinolones, and erythromycin-derived macrolides) and were originally developed as GnRH peptidomimetic antagonists. These structures were selected for this study because of their predicted ability to permeate the cell membrane and interact with a defined affinity with the GnRH receptor. All peptidomimetics studied with an IC50 value (for hGnRHR) <= 2.3 nM had measurable efficacy in rescuing GnRHR mutants, and within a single chemical class, this ability correlated to these IC50 values. Erythromycin-derived macrolides with IC50 values as high as 669.5 nM showed efficacy as rescue compounds. The ability to rescue a particular receptor was a reasonable predictor of the ability to rescue others, even across species lines, although particular mutants could not be rescued by any of the drugs tested.

0022-3565/03/3052-0608$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J EndocrinolHome page
E. Jardon-Valadez, A. Aguilar-Rojas, G. Maya-Nunez, A. Leanos-Miranda, A. Pineiro, P M. Conn, and A. Ulloa-Aguirre
Conformational effects of Lys191 in the human GnRH receptor: mutagenesis and molecular dynamics simulations studies
J. Endocrinol., May 1, 2009; 201(2): 297 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. A. Janovick, A. Patny, R. Mosley, M. T. Goulet, M. D. Altman, T. S. Rush III, A. Cornea, and P. M. Conn
Molecular Mechanism of Action of Pharmacoperone Rescue of Misrouted GPCR Mutants: The GnRH Receptor
Mol. Endocrinol., February 1, 2009; 23(2): 157 - 168.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. J. S. Chee, K. Morl, D. Lindner, N. Merten, G. W. Zamponi, P. E. Light, A. G. Beck-Sickinger, and W. F. Colmers
The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor
J. Biol. Chem., November 28, 2008; 283(48): 33337 - 33346.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. M. Noorwez, D. A. Ostrov, J. H. McDowell, M. P. Krebs, and S. Kaushal
A High-Throughput Screening Method for Small-Molecule Pharmacologic Chaperones of Misfolded Rhodopsin
Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3224 - 3230.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
D. N. Hebert and M. Molinari
In and Out of the ER: Protein Folding, Quality Control, Degradation, and Related Human Diseases
Physiol Rev, October 1, 2007; 87(4): 1377 - 1408.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick
G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo
Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. T. Leskela, P. M. H. Markkanen, E. M. Pietila, J. T. Tuusa, and U. E. Petaja-Repo
Opioid Receptor Pharmacological Chaperones Act by Binding and Stabilizing Newly Synthesized Receptors in the Endoplasmic Reticulum
J. Biol. Chem., August 10, 2007; 282(32): 23171 - 23183.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. A. Janovick, S. P. Brothers, P. E. Knollman, and P. M. Conn
Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand
FASEB J, February 1, 2007; 21(2): 384 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. H. Robben, M. Sze, N. V. A. M. Knoers, and P. M. T. Deen
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus
Am J Physiol Renal Physiol, January 1, 2007; 292(1): F253 - F260.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
P. M. Conn, P. E. Knollman, S. P. Brothers, and J. A. Janovick
Protein Folding as Posttranslational Regulation: Evolution of a Mechanism for Controlled Plasma Membrane Expression of a G Protein-Coupled Receptor
Mol. Endocrinol., December 1, 2006; 20(12): 3035 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
P M. Conn, J. A. Janovick, S. P Brothers, and P. E Knollman
'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation.
J. Endocrinol., July 1, 2006; 190(1): 13 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. M. C. Kong, T. Fan, G. Varghese, B. F. O'Dowd, and S. R. George
Agonist-Induced Cell Surface Trafficking of an Intracellularly Sequestered D1 Dopamine Receptor Homo-Oligomer
Mol. Pharmacol., July 1, 2006; 70(1): 78 - 89.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. R. Hawtin
Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V1a Receptor
J. Biol. Chem., May 26, 2006; 281(21): 14604 - 14614.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. A. Janovick, P. E. Knollman, S. P. Brothers, R. Ayala-Yanez, A. S. Aziz, and P. M. Conn
Regulation of G Protein-coupled Receptor Trafficking by Inefficient Plasma Membrane Expression: MOLECULAR BASIS OF AN EVOLVED STRATEGY
J. Biol. Chem., March 31, 2006; 281(13): 8417 - 8425.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Robert, C. Auzan, M. A. Ventura, and E. Clauser
Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone
J. Biol. Chem., December 23, 2005; 280(51): 42198 - 42206.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. E. Knollman, J. A. Janovick, S. P. Brothers, and P. M. Conn
Parallel Regulation of Membrane Trafficking and Dominant-negative Effects by Misrouted Gonadotropin-releasing Hormone Receptor Mutants
J. Biol. Chem., July 1, 2005; 280(26): 24506 - 24514.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Castro-Fernandez, G. Maya-Nunez, and P. M. Conn
Beyond the Signal Sequence: Protein Routing in Health and Disease
Endocr. Rev., June 1, 2005; 26(4): 479 - 503.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Leanos-Miranda, A. Ulloa-Aguirre, J. A. Janovick, and P. M. Conn
In Vitro Coexpression and Pharmacological Rescue of Mutant Gonadotropin-Releasing Hormone Receptors Causing Hypogonadotropic Hypogonadism in Humans Expressing Compound Heterozygous Alleles
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3001 - 3008.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. J. Pask, H. Kanasaki, U. B. Kaiser, P. M. Conn, J. A. Janovick, D. W. Stockton, D. L. Hess, M. J. Justice, and R. R. Behringer
A Novel Mouse Model of Hypogonadotrophic Hypogonadism: N-Ethyl-N-Nitrosourea-Induced Gonadotropin-Releasing Hormone Receptor Gene Mutation
Mol. Endocrinol., April 1, 2005; 19(4): 972 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. K. Cheng and P. C. K. Leung
Molecular Biology of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Their Receptors in Humans
Endocr. Rev., April 1, 2005; 26(2): 283 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Bonapace, A. Waheed, G. N. Shah, and W. S. Sly
Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17
PNAS, August 17, 2004; 101(33): 12300 - 12305.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. U. Meysing, H. Kanasaki, G. Y. Bedecarrats, J. S. Acierno Jr., P. M. Conn, K. A. Martin, S. B. Seminara, J. E. Hall, W. F. Crowley Jr., and U. B. Kaiser
GNRHR Mutations in a Woman with Idiopathic Hypogonadotropic Hypogonadism Highlight the Differential Sensitivity of Luteinizing Hormone and Follicle-Stimulating Hormone to Gonadotropin-Releasing Hormone
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3189 - 3198.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. P. Brothers, A. Cornea, J. A. Janovick, and P. M. Conn
Human Loss-of-Function Gonadotropin-Releasing Hormone Receptor Mutants Retain Wild-Type Receptors in the Endoplasmic Reticulum: Molecular Basis of the Dominant-Negative Effect
Mol. Endocrinol., July 1, 2004; 18(7): 1787 - 1797.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
A. Ulloa-Aguirre, J. A. Janovick, A. Leanos-Miranda, and P. M. Conn
Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism
Hum. Reprod. Update, March 1, 2004; 10(2): 177 - 192.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. P. Brothers, J. A. Janovick, and P. M. Conn
Unexpected Effects of Epitope and Chimeric Tags on Gonadotropin-Releasing Hormone Receptors: Implications for Understanding the Molecular Etiology of Hypogonadotropic Hypogonadism
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6107 - 6112.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.